Showing results (281-290 of 343) with videos related to
Sort By:
Pageof 35
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2011
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancerV Catalano, F Loupakis, F Graziano, et al.The Journal of Trauma and Acute Care Surgery|August 1, 2012
A multicenter prospective analysis of pediatric trauma activation criteria routinely used in addition to the six criteria of the American College of SurgeonsRichard A Falcone, Lynn Haas, Eileen King, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2015
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trialsY Sunakawa, S Stintzing, S Cao, et al.Journal of the American College of Radiology : JACR|May 5, 2018
ACR Appropriateness Criteria<sup>®</sup> Hematuria-Child, Jonathan R Dillman, Cynthia K Rigsby, et al.ESMO Open|March 6, 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 studyB Borelli, E Fontana, M Giordano, et al.The Pharmacogenomics Journal|June 6, 2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapyA Ruzzo, F Graziano, F Loupakis, et al.Journal of the American College of Radiology : JACR|March 20, 2026
ACR Appropriateness Criteria® Suspected Physical Abuse-Child: Update 2025, David M Mirsky, Dianna M E Bardo, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONOC Cremolini, C Antoniotti, S Lonardi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control studyC Cremolini, F Morano, R Moretto, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2018
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylationF Morano, S Corallo, M Niger, et al.Pageof 35